Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03609268

Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular Carcinoma

Recurrent Hepatocellular Carcinoma Clinical Trial

Official title:
Effects of Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular Carcinoma: a Prospective, Randomized Controlled Study

Clinical Trial Summary

The prognosis of small liver cancer (≤5 cm) who had underwent stereotactic body radiotherapy (SBRT) is encouraging, with the 1-year local control rate has been reported to be 95-100%, 3-year local control rate about 91%, 3-year overall survival rate around 70%. Local ablation therapy has become the standard treatment for recurrent liver cancer after surgery and interventional treatment. The ablation rate of tumors with a diameter of 3.1-5.0 cm reached 90%. The 1, 2, and 3-year survival rates had been reported to be 89%, 74%, and 60%, respectively, which is similar to that of surgical resection. At present, there is no randomized controlled study of SBRT and microwave ablation (MWA) for small liver cancer. It is hoped that this study will further compare the efficacy of SBRT and MWA for recurrent small hepatocellular carcinoma.

Clinical Trial Description

Recurrent small hepatocellular carcinoma after surgery or local ablation therapy are chose for this study. The patients are divided into two groups randomly. Patients in group A receive MWA, group B patients receive SBRT. The 3-year progression free survival, 3-year local recurrence free survival, 3-year overall survival and other endpoints events were recorded and analyzed, to assess whether SBRT is non-inferior to MWA. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03609268
Study type Interventional
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Qichun Wei, MD,PhD
Phone +86 571 87783521
Email qichun_wei@zju.edu.cn
Status Recruiting
Phase N/A
Start date June 30, 2018
Completion date May 31, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04851119 - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Phase 1/Phase 2
Active, not recruiting NCT02143401 - Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Phase 1
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Completed NCT02728219 - Comparison of Treatment of Recurrent HCC With Repeat Hepatectomy,and TACE With AFP Conversion N/A
Active, not recruiting NCT02867592 - Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Phase 2
Active, not recruiting NCT04677088 - TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation Phase 1
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Completed NCT02613156 - Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma N/A
Recruiting NCT02719782 - A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation Phase 1
Recruiting NCT04800497 - The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC
Active, not recruiting NCT03257761 - Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Phase 1
Terminated NCT02762266 - Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization Phase 3
Active, not recruiting NCT03655002 - IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer Phase 1
Withdrawn NCT01318200 - Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC) Phase 3
Completed NCT01015833 - Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Phase 3
Recruiting NCT04663035 - Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC Phase 2
Withdrawn NCT05327738 - Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma Phase 2
Recruiting NCT04615143 - Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC Phase 2
Active, not recruiting NCT04805788 - Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer Phase 2
Withdrawn NCT03634683 - A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation Phase 1/Phase 2